The first and most versatile severely immunodeficient mouse model 

• Immunodeficient model lacking mature T, B, and NK cells
• Displays reduced complement activity
• Has dysfunctional macrophages and dendritic cells
• Displays no leakiness of T and B cells with increasing age
• Very low incidence of lymphoma (unlike NOD scid model)
• Does not develop diabetes
• Excellent model for a variety of xenograft and human cell engraftment studies
• Applications in research involving Cancer, Infectious Disease, Immunology, Regenerative Medicine, Humanization, Autoimmune Disease, Immunotherapy Vaccine, GvHD/Transplantation, Hematopoiesis, Oncology, Inflammation/Allergy, and Safety Assessment
• The Il2rg gene is sex-linked

The hGM-CSF/hIL-3 NOG is an immunodeficient CIEA NOG mouse altered to express human GM-CSF and IL-3 cytokines. The resulting transgenic mouse model supports the differentiation of human myeloid cell lineages and potentiates increased efficiency of hematopoietic stem cell and human immune system engraftment compared to the core NOG mouse.

The model was designed to express relatively low cytokine levels, which maintains the long-term stability of engraftment by preventing the exhaustion of the stem cell pool. This stability makes it a flexible platform for the generation of humanized mice.

• Super immunodeficient NOG mouse expressing human IL-2 cytokine
• Predominant differentiation of human NK cells following human HSC engraftment, with >10-fold higher CD56+ NK cell numbers compared to the base NOG mouse
• Human NK cells developed in hIL-2 NOG mice express various NK receptors and produce both granzyme A and perforin upon stimulation
• May be an improved model for differentiation/engraftment of IL-2 dependent cells including certain blood cancers
• May be useful for efficacy studies involving antibody therapeutics with antibody dependent cell cytotoxcity mechanism of action
• Applications in research involving cancer, infectious disease, immunology, regenerative medicine and human immune system engraftment
• hIL-2 NOG mice produce human IL-2 in the range of 0.5-2.0 ng/mL as measured by MFI serology testing on DBS and serum in February 2023. Based on user feedback, this level appears sufficient to support engraftment of primary human T cells.

• Super immunodeficient NOG mouse expressing human IL-15 cytokine
• Predominant differentiation of human NK cells following human HSC engraftment compared to the base NOG mouse, but survival time is limited
• Engraftment and expansion of human NK cells following engraftment with CD56+ NK cells derived from PBMCs
• hIL-15 NOG mice produce human IL-15 in the range of 1.0-4.0 ng/mL as measured by MFI serology testing on serum in September 2022
• The hIL-15 NOG mouse is optimized for engraftment of isolated primary human NK cells, immortalized human NK cell lines or human NK cell therapies. Humanization with HSCs is not recommended in this model. While HSC engraftment results in strong proliferation of NK cells, lifespan post-differentiation is very limited. Humanization of this strain with PBMCs is not recommended as an optimal model to study human NK cells, but may be of interest for GvHD applications.
• May be useful for efficacy studies involving antibody therapeutics with antibody dependent cell cytotoxcity mechanism of action
• Applications in research involving cancer, infectious disease, immunology, regenerative medicine and human immune system engraftment

• Super immunodeficient NOG mouse expressing human IL-6 cytokine
• Enhanced expansion of human monocytes following human HSC engraftment
• May be useful for study of tumor-infiltrating macrophages
• May be suitable host for hIL-6 dependent multiple myeloma (MM) patient derived xenograft (PDX) and tumor samples
• Applications in research involving cancer, immunology, regenerative medicine and human immune system engraftment

Get a more accurate assessment of your antibody-based drug efficacy. Functional knockout of the murine Fc gamma (Fcγ) improves experimental results to get you the right answer faster.

• The FcResolv™ NOG is a super immunodeficient NOG mouse that has a further reduction in residual murine immune activity via ablation of mouse Fc gamma receptors (FcγRs) to improve accuracy of results.
• Murine FcγRs can confound experiments in several ways, leading to false positive or negative results. Removing murine FcγRs provides improved accuracy for efficacy assessment of antibody-based therapies which include an Fc domain.
• Lacks all murine Fcγ receptors, including the FcγRI, IIB, III and IV types, along with the high affinity FcεRI receptor. The low affinity FcεRII receptor remains present.
• Can be used in a similar fashion to the NOG mouse, including for xenograft and immune system humanization experiments
• FcResolv NOG mice support higher average levels of human cells following engraftment with HSCs compared to the base NO

• Also known as Alb-HSVtk-NOG and albumin-TK-NOG, super immunodeficient NOG mouse with transgenic expression of thymidine kinase under control of liver-restricted albumin promoter
• Useful for humanizing liver via engraftment with human hepatocytes and/or humanizing immune system via engraftment of human immune cells/tissues or hematopoietic stem cells
• Inducible ablation of murine hepatocytes by ganciclovir treatment enables stable, long-term engraftment of human hepatocytes
• The premiere model for human liver toxicity, metabolism, and infectious disease
• Other uses include safety and immunogenicity assessment
• Please note the scientific nomenclature of this strain was updated in Sept 2021 to reflect most current allele designations